Legend Biotech (LEGN) Non-Current Debt (2021 - 2025)

Legend Biotech has reported Non-Current Debt for 5 years, with the latest figure at $319.1 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Debt rose 5.94% year-over-year to $319.1 million; the trailing twelve-month figure through Dec 2025 stood at $319.1 million (up 5.94% YoY), and the FY2025 full-year result was $319.1 million, up 5.94% from the prior year.
• Non-Current Debt for Q4 2025 stood at $319.1 million, up from $142.9 million in the prior quarter.
• The five-year high for Non-Current Debt was $319.1 million in Q4 2025, with the low at $17310.0 in Q2 2021.
• Historically, Non-Current Debt has averaged $230.9 million across 5 years, with a median of $275.9 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Debt surged 116.61% — and 2025, when it plunged 51.83%.
• Legend Biotech's Non-Current Debt stood at $120.5 million in 2021, then surged by 116.61% to $260.9 million in 2022, then rose by 7.82% to $281.3 million in 2023, then climbed by 7.06% to $301.2 million in 2024, then climbed by 5.94% to $319.1 million in 2025.
• The last three Non-Current Debt figures came in at $319.1 million (Q4 2025), $142.9 million (Q3 2025), and $310.3 million (Q2 2025), per Business Quant data.